Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
12.75    -0.25 (-1.92%)
Bid:
12.00
Ask:
13.50
Spread: 1.50 (12.50%)
Market Cap: £15.94m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Update on development

11 Jul 2007 08:16

Fabian Romania Property Fund Ltd11 July 2007 11 July 2007 Fabian Romania Property Fund Limited ("Fabian Romania" or "Fabian") Construction contract agreed and sales started at the New Town residential joint venture development Fabian Romania is pleased to announce that its joint venture developmentcompany, Phoenix Park SRL, has agreed a fixed price build contract with MivanKier for residential apartments at the New Town development in east Bucharest. The development project is now forecast to involve the construction of more than635 residential apartments over two phases with an estimated gross developmentvalue in excess of €120 million and total costs, excluding land, ofapproximately €80 million. The apartments will be approximately 100 squaremetres per unit and are being targeted at middle income families. Building permits have been obtained and below ground construction works areongoing with the first apartments due to be completed in the summer of 2008. A sales and marketing suite was created in central Bucharest and a full launchhas started. To date, 119 apartments with parking have been released for salecomprising the first release. City wide newspaper and radio advertising has beentaken to support the launch. In July 2006, Fabian Romania paid €5.75 million for a 50 per cent. stake in thedevelopment company. Further development funding requirements are expected to bemet by a combination of bank financing and deposits from forward sales. MivanLtd of Country Antrim, Northern Ireland, through its Romanian operating companyRopotamo Expert SRL is acting as the development manager on the project as wellas being Fabian's joint venture partner. Mark Holdsworth, Director of Fabian Capital, Fabian Romania's investment advisersaid: "We are delighted with the progress of the New Town development and ourpartners Mivan. With build costs now secured and a full sales launch underway wehave made significant progress since entering into the joint venture last year.We will provide investors with a further progress report on how well theapartments are selling at the time of the publication of our second quarter NAV,expected on Monday 23 July." Enquiries: Fabian Romania: Mark Holdsworth +44 20 7499 9988 Nominated Adviser: Deloitte & Touche LLP James Lewis +44 20 7936 3000 Broker: Shore Capital Stockbrokers Limited Dru Danford +44 20 7408 4090 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Jun 20267:00 amRNSExercise of options and total voting rights
11th May 20263:06 pmRNSHolding(s) in Company
11th May 202611:05 amRNSGrant of patent in Japan
5th May 20267:00 amRNSYear-end trading statement
30th Mar 20267:00 amRNSAntibody IP transfer agreement
17th Feb 202611:42 amRNSDirector/PDMR Shareholding
4th Feb 20263:27 pmRNSHolding(s) in Company
2nd Feb 202611:33 amRNSHolding(s) in Company
30th Jan 20265:00 pmRNSTotal Voting Rights
27th Jan 20267:05 amRNSIssue of Director Shares
27th Jan 20267:00 amRNSPlacing and Subscription to raise approx £1.4m
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
19th Dec 20257:00 amRNSUpdate on negotiations with NCI regarding OptiMAL
16th Dec 202511:04 amRNSLaunch of OptiMAL platform
11th Dec 20257:00 amRNS-RMammalian Display video
25th Nov 202512:11 pmRNSHolding(s) in Company
24th Nov 20257:00 amRNSHalf-year Financial Report
21st Nov 20257:00 amRNSNotice of Results
13th Nov 20257:00 amRNS-ROptiMAL Library video
3rd Nov 20257:00 amRNSOptiMAL® R&D Update
27th Oct 20253:38 pmRNSHolding(s) in Company
16th Oct 20251:31 pmRNSResult of AGM
16th Oct 20257:00 amRNSAGM statement and H1 trading update
8th Oct 20257:00 amRNSContract win
19th Sep 202512:58 pmRNSPosting of Annual Report & Notice of AGM
17th Sep 20257:00 amRNSOptiMAL R&D Update
8th Sep 20257:00 amRNS-RBelfast investor presentation
4th Sep 20257:00 amRNSFinal Results
28th Aug 20257:00 amRNSContract Win
27th Aug 20257:00 amRNSContract wins with existing client
26th Aug 20257:00 amRNS-RInvestor presentations
5th Aug 20257:00 amRNSGrant of U.S. Patent for OptiMAL
24th Jul 202510:56 amRNSIssue Notification: US Patent Update
11th Jul 20257:00 amRNSDirector/PDMR Shareholding
2nd Jun 20257:00 amRNSTotal Voting Rights
22nd May 20252:33 pmRNSUpdate on U.S. Patent for OptiMAL®
8th May 20257:00 amRNS-RInvestor presentation
7th May 20257:00 amRNSIssue of shares to non-executive directors
6th May 202510:53 amRNSDirector/PDMR Shareholding
6th May 202510:38 amRNSHolding(s) in Company
6th May 20257:00 amRNSTrading update
30th Apr 20255:00 pmRNSTotal Voting Rights
24th Apr 20257:00 amRNSApproval of grant funding
11th Apr 202510:40 amRNSHolding(s) in Company
10th Apr 202512:47 pmRNSHolding(s) in Company
7th Apr 202512:35 pmRNSResult of General Meeting
31st Mar 20255:00 pmRNSTotal Voting Rights
24th Mar 20254:38 pmRNSHolding(s) in Company
18th Mar 20257:00 amRNSPlacing to raise approximately £1.17 million
27th Feb 20257:00 amRNSContract win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.